Objective: To summarize the experience of diagnosis and treatment outcomes for bone metastatic prostate cancer. Methods: A retrospective study with a total of 128 prostate cancer (Pca) was performed from 2000 to 2005, in our institute. We analyzed the clinical features and outcomes of patients with bone metastases and the data and follow-up of 63 bone metastases was collected by one registrar. Cochran Armitage trend test was used for statistic analysis and a P-value of < 0.05 was taken as statistically significant. Results: The mean age was 73 (range 55 to 87) years. The PSA level was from 0.083 ng/mL to 6462 ng/mL. Bone metastases morbidity had good relationship with PSA level. With the mean follow up of 30 (range 6 to 72) months for 52/63 (82.5%) patients, 15 (28.8%) died from Pea with a mean survival of 21 months and 1 patient with PSA less than 4 ng/mL at the time died from cerebrovascular suddenness 6 months post-treatment. Conclusion: The early effect of endocrine treatment for bone metastases is obvious, and palliative prostatectomy is satisfactory and able to improve the quality of life rapidly for patients with obstructive symptoms.